Second, severe toxicities to essential anti‐HER2 agents, including infusion reactions and ILD, can often be managed through desensitization, aggressive supportive care, and personalized dose modifications, allowing patients to derive sustained benefit from these potent therapies. Here, ERBB2 is linked to interstitial lung disease.